Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $181.29 million. The enterprise value is $224.52 million.
| Market Cap | 181.29M |
| Enterprise Value | 224.52M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 71.75 million shares outstanding.
| Shares Outstanding | 71.75M |
| Owned by Insiders (%) | 12.13% |
| Owned by Institutions (%) | 18.83% |
| Float | 33.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.76 |
| Forward PS | 9.03 |
| PB Ratio | 2.34 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 1.32.
| Current Ratio | 2.20 |
| Quick Ratio | 2.00 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.07 |
Financial Efficiency
Return on equity (ROE) is -84.10% and return on invested capital (ROIC) is -31.12%.
| Return on Equity (ROE) | -84.10% |
| Return on Assets (ROA) | -35.80% |
| Return on Capital (ROIC) | -31.12% |
| Revenue Per Employee | $105,671 |
| Profits Per Employee | -$368,013 |
| Employee Count | 231 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cellectis has paid $481,153 in taxes.
| Income Tax | 481,153 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.79% in the last 52 weeks. The beta is 3.13, so Cellectis's price volatility has been higher than the market average.
| Beta (1Y) | 3.13 |
| 52-Week Price Change | +36.79% |
| 50-Day Moving Average | 2.65 |
| 200-Day Moving Average | 2.39 |
| Relative Strength Index (RSI) | 50.96 |
| Average Volume (30 Days) | 37,838 |
Short Selling Information
| Short Interest | 676,477 |
| Short Previous Month | 679,269 |
| Short % of Shares Out | 4.09% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 19.61 |
Income Statement
In the last 12 months, Cellectis had revenue of $24.41 million and -$85.01 million in losses. Loss per share was -$1.76.
| Revenue | 24.41M |
| Gross Profit | 24.64M |
| Operating Income | -58.45M |
| Pretax Income | -90.01M |
| Net Income | -85.01M |
| EBITDA | -29.11M |
| EBIT | -46.47M |
| Loss Per Share | -$1.76 |
Balance Sheet
The company has $71.70 million in cash and $106.80 million in debt, giving a net cash position of -$35.09 million or -$0.49 per share.
| Cash & Cash Equivalents | 71.70M |
| Total Debt | 106.80M |
| Net Cash | -35.09M |
| Net Cash Per Share | -$0.49 |
| Equity / Book Value | 81.03M |
| Book Value Per Share | 1.13 |
| Working Capital | 55.93M |
Cash Flow
In the last 12 months, operating cash flow was -$69.92 million and capital expenditures -$371,509, giving a free cash flow of -$70.29 million.
| Operating Cash Flow | -69.92M |
| Capital Expenditures | -371,509 |
| Free Cash Flow | -70.29M |
| FCF Per Share | -$1.26 |
Margins
Gross margin is 100.95%, with operating and profit margins of -239.44% and -348.26%.
| Gross Margin | 100.95% |
| Operating Margin | -239.44% |
| Pretax Margin | -368.75% |
| Profit Margin | -348.26% |
| EBITDA Margin | -119.25% |
| EBIT Margin | -190.39% |
| FCF Margin | -287.96% |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.20% |
| Shareholder Yield | -22.20% |
| Earnings Yield | -44.88% |
| FCF Yield | -37.11% |
Analyst Forecast
The average price target for Cellectis is $8.50, which is 224.43% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.50 |
| Price Target Difference | 224.43% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 28.03% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -1.9 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.9 |
| Piotroski F-Score | 3 |